Share this article
Share this article
NEW YORK and PUNE, India, Dec. 14, 2020 /PRNewswire/ Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19, that was shown to be safe and efficacious in preclinical animal studies. COVI-VAC was developed with Codagenix s Synthetic Attenuated Virus Engineering (
SAVE) platform that uses synthetic biology to re-code the genes of viruses into safe and stable vaccines. COVI-VAC is designed to deliver a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus.
Serum Institute announces first-in-human trial of COVI-VAC
Serum Institute announces first-in-human trial of COVI-VAC
15 December 2020 | News With the Phase 1 trial now initiated, Codagenix and Serum Institute of India expect to begin advanced clinical testing in mid-2021.
Image Credit: shutterstock.com
US-based Codagenix and Serum Institute of India Pvt. Ltd. have announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19, that was shown to be safe and efficacious in preclinical animal studies.
COVID-19 Vaccine| Representational Image (Photo Credits: IANS)
New Delhi, Dec 11: The World Health Organization (WHO), national regulatory authorities and vaccine manufacturers in WHO South-East Asia Region discussed fast-tracking of Covid-19 vaccine rollout in member countries. The vaccine manufacturing and regulatory sectors have a critical role to play inequitable and efficient deployment of vaccines, said Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region.
Aimed at strengthening collaboration between national programmes, vaccine producers and regulators in the region for Covid-19 vaccine deployment, the meeting provided a platform for interaction and experience sharing for vaccine registration, deployment and regulation.
According to Singh, all countries in the Region are now developing and finalizing national deployment and vaccination plans for Covid-19, of which regulatory preparedness is a core component.
Deal signed with India s Serum Institute for Covid-19 vaccine jagonews24.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jagonews24.com Daily Mail and Mail on Sunday newspapers.
The World Health Organization (WHO), national regulatory authorities and vaccine manufacturers in WHO South-East Asia Region discussed fast-tracking of Covid-19 vaccine rollout in member countries. The vaccine manufacturing and regulatory sectors have a critical role to play inequitable and efficient deployment of vaccines, said Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region. Aimed at strengthening collaboration between national programmes, vaccine producers and regulators in the region for Covid-19 vaccine deployment, the meeting provided a platform for interaction and experience sharing for vaccine registration, deployment and regulation. According to Singh, all countries in the Region are now developing and finalizing national deployment and vaccination plans for Covid-19, of which regulatory preparedness is a core component.